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Abstract 9 
Reductive amination is one of the most important methods for the synthesis of chiral amines. Here we 10 
report the discovery of an NADP(H)-dependent reductive aminase from Aspergillus oryzae 11 
(AspRedAm, Uniprot code Q2TW47) which can catalyse the reductive coupling of a broad set of 12 
carbonyl compounds with a variety of primary and secondary amines with up to >98% conversion and 13 
with up to >98% enantiomeric excess. In cases where both carbonyl and amine show high reactivity, it 14 
is possible to employ a 1:1 ratio of the substrates, forming amine products with up to 94% conversion. 15 
Steady-state kinetic studies establish that the enzyme is capable of catalysing imine formation as well 16 
as reduction. Crystal structures of AspRedAm in complex with NADP(H) and also with both NADP(H) 17 
and the pharmaceutical ingredient (R)-rasagiline are reported. We also demonstrate preparative scale 18 
reductive aminations with wild-type and Q240A variant biocatalysts displaying total turnover 19 
numbers of up to 32,000 and space time yields up to 3.73 g L-1 d-1.  20 
 21 
An analysis of drugs approved by the FDA in recent years reveals that ca. 40% of new chemical entities 22 
(NCEs) contain one or more chiral amine building blocks.1 This sustained prevalence of chiral amines in 23 
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APIs has driven the development of new and efficient catalytic methods for chiral amine synthesis that 24 
have broad application.26 In this context, the reductive amination of ketones is one of the most 25 
powerful and frequently employed reactions for amine synthesis, enabling a wide range of ketones to be 26 
coupled to primary and secondary amines.711  27 
In view of the fact that the products are often chiral, there is an increasing desire to develop asymmetric 28 
variants of this reaction, particularly utilising chemo- or biocatalysis. Specifically, transition metal-29 
catalysed reductive amination and enantioselective enamide reduction approaches8 to chiral amines 30 
have received considerable attention as well as biocatalytic routes employing transaminases,6,1214 31 
ammonia lyases1517 or monoamine oxidases.1820  32 
In addition, a number of distinct enzyme families have previously been reported to catalyse the 33 
reductive amination of ketones. The NADPH-dependent octopine dehydrogenases (OctDHs) catalyse the 34 
coupling of α-amino acids with α-keto acids and have been the focus of recent attempts to broaden 35 
their substrate range using protein engineering.21 Amino acid dehydrogenases (AADHs) perform 36 
aminations of α-keto acids with ammonia by first catalysing formation of α-imino acids followed by 37 
NADPH-dependent reduction to yield α-amino acids. Although AADHs have been engineered to accept 38 
simple unfunctionalised ketones, they typically show strict specificity for ammonia as the amine 39 
nucleophile.22,23 The related N-methyl-amino acid dehydrogenases (NMAADHs) use methylamine to 40 
generate the corresponding N-methyl-amino acids.24 Recently, reductive amination has also been 41 
demonstrated using imine reductases (IREDs).2528 However, the reactions have involved the use of large 42 
quantities of IRED enzyme, and ratios of amine to ketone ranging from ca. 50:126 to 12.5:127 in order to 43 
achieve the conversions. This low reactivity of IREDs for the catalysis of reductive amination is almost 44 
certainly due to the fact that their principal role is to catalyse the reduction of preformed cyclic imines.29 45 
For example, we3034 and others25,26,35,36 have shown that IREDs catalyse the asymmetric reduction of a 46 
wide range of 5-, 6-, and 7-membered imines with good conversions and high enantioselectivity. 47 
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Importantly, from a mechanistic viewpoint, OctDHs, AADHs and NMAADHs have been shown to catalyse 48 
imine formation, whereas the IREDs described so far have not.2527 Thus, one important goal is to 49 
identify an enzyme scaffold which can combine (i) high activity for imine formation from ketone and 50 
amine; (ii) high enantioselectivity for imine reduction and (iii) broad substrate tolerance with respect to 51 
both amines and ketones. Herein we report our efforts to find and develop an enzyme that possesses 52 
these properties through the discovery and investigation of a reductive aminase (RedAm) (Figure 1). 53 
Results and Discussion 54 
Identification of AspRedAm 55 
A reductive aminase from Aspergillus oryzae (AspRedAm), the first IRED homolog from a eukaryotic 56 
source, was initially identified based upon its sequence similarity to known IREDs including those from 57 
Amycolatopsis orientalis (AoIRED)34 and Streptomyces sp.3739 Those IREDs have been shown to possess 58 
high activity for imine reduction but modest to poor activity for reductive amination. Following cloning 59 
and expression of the gene encoding AspRedAm in E. coli, the purified enzyme was revealed to have 60 
remarkable potency as a catalyst of reductive amination. The characterisation of AspRedAm using 61 
biotransformations, kinetic and structural studies suggests it is representative of a subclass of IREDs that 62 
have evolved to possess a particular capability for reductive amination reactions. 63 
Investigation of substrate specificity of AspRedAm 64 
The relative specific activity of AspRedAm towards a representative library of carbonyl acceptors 1-32 65 
was determined using propargylamine a and methylamine g as substrates, with the amine and NADPH 66 
concentrations maintained at saturation (Supplementary Section 7.1, Table 10). In order to assess the 67 
amine substrate scope, the relative specific activities of AspRedAm with cyclohexanone 1 and 4-phenyl-68 
2-butanone 17 were also measured towards amines a-s (Supplementary Section 7.2, Table 11).  69 
AspRedAm exhibited higher specific activity for 1 with a (6.68 U mg-1) and with allylamine c (7.68 U mg-1) 70 
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compared to g (2.23 U mg-1), highlighting the contribution of the amine partner to the catalytic rates.  A 71 
clear preference for cyclic ketones was observed (e.g. 1 and 4) and C5 or C6 linear ketones and 72 
aldehydes (e.g. hexanal 3, 2,5-hexanedione 5, 2-hexanone 6) were transformed faster than C4 carbonyl 73 
compounds (e.g. 2-butanone 26). The screening of amine nucleophiles revealed a greater activity of 74 
AspRedAm towards primary amines, especially unsaturated aliphatic amines (a and c). Excellent activity 75 
was observed with cyclopropylamine b, however the activity was significantly lower when 76 
isopropylamine n was used as a nucleophile. In the presence of reactive carbonyl acceptors (e.g. 1), 77 
amination with various amines, including N-methylprop-1-yn-1-amine j, pyrrolidine l, piperidine p, 78 
ammonia k and hydroxylamine q, proceeded with activities of up to 0.7 U mg-1.  However, with a less 79 
reactive carbonyl acceptor (e.g. 17), lower rates were observed with these reacting partners, although 80 
primary amines were tolerated.  81 
 82 
By combining the data of relative specific activities towards the carbonyl acceptors and amine partners 83 
(Supplementary Section 7, Table 10 and Table 11) we generated a reactivity chart to act as a predictive 84 
tool for the likely outcome of reductive amination between specific ketones and amines (Figure 2). The 85 
chart was constructed by combining the average relative activities of representative carbonyl 86 
compounds, measured with two amine nucleophiles (a and g), and plotting this against the average 87 
relative specific activities of amine nucleophiles measured with two ketones (1 and 17). The carbonyl 88 
compounds and amines were arranged in Groups I-IV and Groups A-C respectively based on their 89 
average relative specific activity value. For ketone-amine combinations that have high relative specific 90 
activities for both reacting partners (i.e. Groups I and II vs. Group A, Figure 2) it is likely that high-yielding 91 
reductive aminations can be achieved with AspRedAm with near stoichiometric equivalents of ketone 92 
and amine. Increasing the amine equivalents can improve conversions for substrates that have less 93 
favourable specific activities (i.e. Groups III and IV vs. Group B and C, Figure 2). 94 
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 95 
 96 
Using the reactivity chart as a guide, a series of biotransformations was performed with a range of 97 
carbonyl and amine combinations (Table 1). AspRedAm reactions with both cyclic and acyclic ketones 98 
afforded products in moderate to excellent conversion and enantioselectivity. In several cases, 99 
equimolar concentrations of ketone and amine gave high conversions (Table 1, products 1a, 1b, 1c, 1m), 100 
which is indicative of genuine AspRedAm-catalysed reductive amination processes. Ammonia k and 101 
secondary amines l and p were also accepted as reacting partners when coupled with particularly active 102 
carbonyls (Table 1, products 1k, 9k, 19p, 19p). In the AspRedAm-catalysed reaction between 103 
benzaldehyde 19 and k, the initial product of reductive amination was benzylamine m which acts as an 104 
amine reacting partner for a second reductive amination with the ketone substrate, resulting in product 105 
19m. Reductive amination of ethyl levulinate 10 afforded N-alkylpyrrolidinones (10a-b) as products 106 
following spontaneous cyclisation. Interestingly, AspRedAm could also distinguish to some extent 107 
between (R)- and (S)-sec-butylamine t as the amine coupling partner with (S)-t giving higher conversion. 108 
Furthermore, AspRedAm was able to directly produce the active pharmaceutical ingredient (API) (R)-109 
rasagiline 29a starting from 1-indanone 29 and a in 64% conversion and 95% e.e. 110 
111 
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AspRedAm versus IREDs 112 
As an IRED homolog, purified AspRedAm displayed broad substrate scope in the reduction of cyclic and 113 
preformed imines and iminium ions, allowing access to secondary and tertiary amines. For example, 114 
dihydroisoquinoline derivative 45 was transformed to the natural product salsolidine 46 with >99% 115 
conversion and >99% e.e. (Supplementary Section 8). AspRedAm was also able to act in the reverse, 116 
oxidative direction and exhibited activity in the dehydrogenation of amines to yield imines. The highest 117 
activity was found for 1-methyl-tetrahydroquinoline 34 and acyclic amines were also found to be 118 
transformed (Supplementary Section 7, Table 12). This reactivity was exploited in the efficient kinetic 119 
resolution of rasagiline rac-29a to give the (S)-enantiomer in 49% conversion and 99% e.e. Interestingly, 120 
the enzyme displayed regioselectivity in the deamination as only indanone 29, a and (S)-29a were 121 
detected after a 24-hour biotransformation of rac-29a.  122 
To further investigate the unusual catalytic features of AspRedAm, we compared its reductive amination 123 
activity to those of the IRED from Streptomyces sp. GF3587 (R-IRED)31,38 and the Amycolatopsis orientalis 124 
IRED (AoIRED).34 For enzymes only capable of reducing preformed imines, we anticipated that reductive 125 
amination activity with aldehydes would be highly dependent on pH, as it has been reported that 126 
spontaneous imine formation between benzaldehyde and methylamine in aqueous solution is 127 
insignificant at pH 7.6 (4%) but considerable at pH 9.0 (87%).26 Conversely, for ketones, spontaneous 128 
imine formation is negligible at both pHs and, therefore, reductive amination activity is less likely to be 129 
pH dependent.  130 
Initial rate measurements of the selected IREDs were performed at pH 7.0 and 9.0 using 1 and 3 with c 131 
(Supplementary Section 12). AspRedAm displayed much higher specific activities than R-IRED and 132 
AoIRED for the reductive amination of both 1 and 3 regardless of pH. In the reductive amination of 3, an 133 
approximate 20-fold improvement in specific activity was observed for R-IRED and AoIRED when the pH 134 
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was increased from 7.0 to 9.0. This correlates with the difference in the imine concentration in aqueous 135 
media at different pHs that was previously reported and further suggests that these IREDs rely on 136 
preformed imine in solution which they are then able to reduce.26 Remarkably, the specific activity of 137 
AspRedAm only increased 1.3-fold, showing that the spontaneous imine formation in solution is not 138 
essential for this enzyme. For the reductive amination of 1, there was no significant change in activity 139 
from pH 7.0 to 9.0 with AspRedAm, AoIRED or R-IRED. The high specific activity of AspRedAm at pH 7.0 140 
and pH 9.0 for reactions with both 1 and 3 is indicative of the role of AspRedAm in catalysing both the 141 
formation of imine and its subsequent reduction. The differences between AspRedAm and other IREDs 142 
are further highlighted by sequence comparison and structure studies, reported herein. 143 
 144 
A Kinetic Model for AspRedAm Activity 145 
AspRedAm-catalysed reductive amination of ketones follows the MichaelisMenten model based on 146 
initial rate studies. For a selected substrate panel, AspRedAm exhibited high activity in many cases; for 147 
example, the kcat for AspRedAm-catalysed reductive amination of 1 and c was 5 s
-1 (Supplementary 148 
Section 6.2). In order to further probe the mechanism of AspRedAm-catalysed reductive amination we 149 
carried out detailed steady-state kinetic studies using 1 and g as substrates (Supplementary Section 6). 150 
We simultaneously varied the concentration of 1 and g while NADPH was held at saturation; the 151 
resulting double-reciprocal plots (1/vi versus 1/[1]) yielded patterns of lines that intersected to the left 152 
of the 1/v axis. When g was held at saturation and the NADPH concentration varied at different fixed 153 
concentrations of 1, a similar intersecting pattern of lines was obtained.  The intersecting lines were also 154 
obtained when 1 was held at a constant level, and NADPH was varied at fixed concentration of g.  These 155 
patterns are consistent with a sequential mechanism and rule out a ping-pong mechanism for 156 
AspRedAm activity. 157 
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To investigate the order of substrate addition and product release, product inhibition studies were 158 
conducted in the forward and reverse directions (Supplementary Section 6.4). In the forward direction, 159 
inhibition by NADP+ is linearly competitive with respect to NADPH, uncompetitive with respect to 1 and 160 
non-competitive with respect to g. In the reverse reaction, NADPH behaves as a linear competitive and 161 
non-competitive inhibitor with respect to NADP+ and 1g respectively. This inhibition pattern indicates 162 
that NADPH is the first substrate to bind while NADP+ is the last product released in the forward 163 
reaction.40,41 Inhibition by 1g was non-competitive with respect to NADPH, 1 and g. This pattern is 164 
consistent with 1g being the first product to be released in the forward direction.40,41 In the reverse 165 
direction, g behaves as a non-competitive inhibitor with respect to NADP+ and 1g indicating that g is the 166 
first substrate to be released in the oxidation of 1g and the last substrate to bind in the forward 167 
direction. Inhibition by 1 was uncompetitive with respect to NADP+ and 1g in the forward direction, as 168 
would be expected of the substrate binding second in the sequence. 169 
The kinetic behaviour observed when the concentrations of two substrates were simultaneously varied 170 
alongside the patterns of inhibition obtained from the product inhibition studies showed that 171 
AspRedAm-catalysed reductive coupling of 1 and g to form 1g follows an ordered sequential Ter Bi 172 
mechanism.  The cofactor NADPH, the ketone 1 and the amine g are added to the enzyme in that 173 
sequence followed by the release of product 1g and NADP+ (Figure 3). The AspRedAm-catalysed 174 
reductive amination follows the kinetic model displayed by N-methyl-L-amino acid dehydrogenase from 175 
Pseudomonas putida with the same order of binding of substrates.24 Other enzymes that catalyse imine 176 
formation  also operate via a Ter Bi mechanism such as number of ɲ-keto dehydrogenases4246 and  177 
opine dehydrogenases (OpDHs)41,47,  however, the order of ketone and amine binding can be different. 178 
 179 
 180 
 181 
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Crystal Structure of AspRedAm and mutagenesis studies 182 
The exceptional properties of AspRedAm prompted us to examine its structure using X-ray 183 
crystallography, and to compare it with IREDs that are not capable of catalysing equimolar reductive 184 
amination reactions. Co-crystallisation of AspRedAm with 29, amine a and NADPH resulted in a ternary 185 
complex, in which both NADP(H) and the product, (R)-29a, were found in the active site. The crystals 186 
were in the P1 space group, and four dimers were found in the asymmetric unit.  AspRedAm possesses 187 
the canonical IRED fold, in which two monomers, each made up of an N-terminal Rossman domain and a 188 
C-terminal helical bundle connected by a long inter-domain α-helix, associate to form a functional dimer 189 
in which the active site forms at the interface between the N- and C-terminal domains of different 190 
monomers (Figure 4A). In contrast to other IRED structures however, the ternary complex of AspRedAm 191 
is significantly more compact, with a relative movement between domains closing the active site over 192 
the NADP(H) and the product ligand to form a much smaller active site than has been observed in open 193 
forms of IREDs previously.3134,48,49  194 
 195 
The ligand was bound within a hydrophobic pocket previously identified in the IRED from AoIRED34 196 
adjacent to the (Si)-face of the nicotinamide ring of NAD(P)H. The ligand is somewhat mobile in the eight 197 
active sites in the asymmetric unit, but the nitrogen atom of the amine is 3.2-4.9 Å (4.5 Å in the case 198 
shown in Figure 4B) from the phenolic hydroxyl of Y177, suggesting a role in either proton donation or 199 
product anchoring by this residue.  Mutation of Y177 to alanine resulted in a mutant Y177A with about a 200 
30-fold decrease in reductive aminase activity compared to the wild-type enzyme (Figure 4C). The ligand 201 
conformation in Figure 4B also positions the electrophilic carbon of the amine product at between 202 
approximately 3.4 and 4.2 Å from C4 of the nicotinamide ring of NAD(P)H (3.8 Å in the case shown in 203 
Figure 4B), an ideal distance for hydride delivery/acceptance. It was also interesting that mutation of 204 
D169, which has been thought to have a role in catalysis in some IREDs,33 resulted in variants D169A and 205 
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D169N of significantly reduced reductive aminase activity (Figure 4C).  Both mutants showed a ca. 200-206 
fold decrease in reductive amination activity compared to the wild-type enzyme.  Other residues of 207 
possible significance are N93, which hydrogen bonds to D169, Q240 and M239 at the front of the picture 208 
in Figure 4B that are brought nearly into contact with the ligand upon closure of the active site, and 209 
W210 at the back of the picture, which helps to complete the hydrophobic pocket. 210 
The characterisation of the active site of AspRedAm provided a basis for searching the sequence 211 
databases for other enzymes of similar properties, and also to compare the enzyme against IREDs 212 
reported previously, which have not displayed equimolar reductive aminase activity.  A number of other 213 
sequences from filamentous fungi, including Aspergillus terreus (AtRedAm) and Ajellomyces dermatitidis 214 
(AdRedAm) were identified that each contained residues equivalent to N93, D169, Y177, W210, M239 215 
and Q240 in AspRedAm.  The genes encoding AtRedAm and AdRedAm were cloned and expressed in E. 216 
coli and, following purification of the enzymes, we were able to confirm asymmetric reductive amination 217 
using a 1:1 ratio of amines a, c and g and ketone 1 as a property of these enzymes (Supplementary 218 
Section 11.3, Table 17).  A phylogenetic tree that compares these fungal RedAms with sequences of 219 
enzymes for which non-equimolar reductive amination reactions have been reported26,27,48 shows that 220 
fungal RedAms form a distinct sub-group (Supplementary Section 11.1, Figure 67). Analysis of the 221 
sequences of these enzymes reveals that while one or two bacterial IREDs may feature some of the 222 
active site residues of RedAms, none of the bacterial homologs is likely to contain all of them within the 223 
active site (Supplementary Section 11.2, Table 16).  IR_9 and IR_23, described by Wetzl and co-224 
workers27,35 are most similar, containing five and four out of the six residues respectively, but each has a 225 
threonine residue in the place of asparagine in positions equivalent to 93 in RedAms.  A direct 226 
comparison of AspRedAm with IR_23 shows that the former catalysed the formation of amine 1g with 227 
84% conversion at a ketone:amine ratio of 1:2; IR_23 was reported to catalyse this transformation with 228 
80% conversion, but only at a ketone:amine ratio of 1:12.5.27 Whilst we cannot conclude that these six 229 
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residues uniquely describe the requirements of a RedAm active site, their identification should prove a 230 
useful guide to the identification of further RedAm enzymes in the sequence databases. 231 
The structure of AspRedAm suggested that W210 and Q240 may be good target residues to mutate in 232 
order to alter substrate specificity. Indeed, the W210A variant displayed a dramatic selectivity switch to 233 
yield the antipodal (S)-amine products upon the reductive amination of 17 with a variety of amine 234 
nucleophiles (Table 2, entries 1-4, Supplementary Section 9.1, Figure 66). (S)-Selectivity was also 235 
observed when a was reductively coupled with 2-tetralone 9 (Table 2, entry 6), as well as in the coupling 236 
of 10 with c to form the N-substituted lactam 10c. Variant W210S displayed similar stereoselective 237 
properties to W210A, with the (S)-amine products formed upon the reductive amination of a panel of 238 
substrates (Table 2). From the determination of the kinetic parameters, both W210A and W210S 239 
displayed similar activity profiles although W210A appeared to be slightly more active (Supplementary 240 
Section 9, Table 14). Interestingly, the Q240A variant displayed significant improvements in (R)-241 
selectivity for most substrates compared to the wild-type enzyme. For example, the enantioselectivity in 242 
the reductive amination of 17 with c was greatly improved (94% e.e.) compared to the wild-type (30% 243 
e.e. Table 2, entry 1).  The Q240A variant was also capable of coupling k to 17 to yield the primary chiral 244 
amine 17k in excellent e.e. (>98%). The significant improvement in the (R)-selectivity of AspRedAm 245 
Q240A also permitted the successful synthesis of (R)-29a in >98% conversion with >98% e.e. using this 246 
mutant. 247 
 248 
Preparative-Scale Reductive Aminations using AspRedAm 249 
To test the synthetic applicability of AspRedAm, a series of preparative-scale reactions were performed. 250 
Taking 1 and g as model substrates, certain process parameters were investigated on an analytical-scale 251 
prior to implementing the reaction on a larger scale. The concentration of ketone, the number of amine 252 
equivalents and the enzyme loading were investigated (Supplementary Section 13, Table 18). 253 
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Interestingly, excellent conversion (>97%) could be achieved using 50 mM 1, 2 amine equivalents and 254 
0.1 mg mL-1 AspRedAm and so these conditions were employed for the 100 mg scale synthesis of 1g, 255 
which was isolated as a hydrochloride salt, in 75% yield. A variety of other reductive amination products 256 
1a, 6g, 10a and 17g were successfully recovered with either wild-type AspRedAm or the Q240A variant 257 
on a preparative scale to afford products in good to excellent isolated yields of 70%, 70%, 48% and 78% 258 
respectively after hydrochloride salt formation or column chromatography (Supplementary Section 13). 259 
These reactions compare favourably with other preparative biocatalytic processes50,51 with total 260 
turnover numbers (TTNs) up to 32,000, turnover frequencies (TOFs) up to 300 min-1 and space time 261 
yields (STYs) up to 3.73 g L-1 d-1.  262 
 263 
Conclusion 264 
In summary, we report the discovery and characterization of a reductive aminase from Aspergillus 265 
oryzae (AspRedAm) which has been shown to possess remarkably high activity for the reductive 266 
amination of ketones and amines, often with high stereoselectivity and in some cases with 267 
ketone:amine ratios as low as 1:1. By examining the relative activities of a broad range of different 268 
amines and ketones it has been possible to construct a predictive reactivity chart in which the likely 269 
outcome of a reductive amination reaction can be appraised. We also present detailed kinetic studies, to 270 
support the order of substrate binding and product release, together with an X-ray crystal structure of a 271 
ternary complex of AspRedAm which has been used to inform mutagenesis studies and has allowed us 272 
to identify key active-site residues that may be involved in ligand binding and catalysis. The 273 
demonstrated activity in the reductive amination of aldehydes between pH 7.0 and 9.0 provides further 274 
evidence that AspRedAm catalyses imine formation. Finally we have illustrated the synthetic potential of 275 
AspRedAm through the reductive amination of a number of ketone substrates and successfully 276 
demonstrated the preparative-scale synthesis of a selection of amine products. Taken together, these 277 
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results serve to highlight RedAms as an important sub-group of IREDs that possess unique and attractive 278 
properties for the biocatalytic preparation of industrially important amines.  279 
 280 
  281 
EXPERIMENTAL SECTION 282 
General 283 
For full details of synthetic procedures and characterisation data, see Supplementary Information.  284 
Gene synthesis, cloning, expression and protein purification 285 
The codon-optimized gene sequence encoding AspRedAm (GenBank accession number, KY327363) was 286 
sub-cloned into pET28a-(+) vector form pET 28a-His-AspRedAm plasmid (Figure S2). Site-directed 287 
mutagenesis for the creation of AspRedAm variants were performed using primers as listed in the 288 
Supplementary Information (Section 3.2). Cultivation was performed in 500 mL 2x YT broth medium 289 
with kanamycin (30 ʅgരmL-1). Cultures were initially incubated at 37°C with shaking at 250 rpm. At an 290 
optical density (OD600nm) of between 0.6 and 0.8, isopropyl ɴ-D-1-thiogalactopyranoside (IPTG) was 291 
added to a final concentration of 0.5 mM to induce the expression of AspRedAm. Incubation was 292 
continued at 20°C and 250 rpm for 18 h.  Cells were then harvested by centrifugation and resuspended 293 
in sodium phosphate buffer (100 mM, pH 7.5).  Cells were disrupted by ultrasonication at 0°C. The 294 
enzyme was purified from the clarified lysate by Ni-affinity chromatography. To further purify the 295 
protein for crystallisation, size exclusion chromatography (SEC) was performed in Tris-HCl buffer (50 296 
mM, pH 8.0) containing 500 mM NaCl. The protein concentration was determined using the Bradford 297 
assay against BSA as a concentration standard. Further details and general information on strains and 298 
plasmids, and details of gene design and cloning protocols can be found in the Supplementary 299 
Information (Section 3).   300 
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Biotransformations 301 
Typical procedure for AspRedAm-catalysed reductive amination: a 500 µL reaction mixture contained 30 302 
mM D-glucose, 0.4 mg mL-1 GDH (Codexis, CDX-901), 1 mM NADP+, 1 mg mL-1 purified AspRedAm, 5 mM 303 
carbonyl compound, the appropriate ratio of amine nucleophile (in buffer adjusted to pH 9.0) and 2% 304 
(v/v) dimethylformamide or dimethylsulfoxide. The reaction volume was made up to 500 µL with Tris-305 
HCl buffer (100 mM, pH 9.0). Reactions were incubated at 25°C with shaking at 250 rpm for 24 h, after 306 
which they were quenched by the addition of 30 µL of 10 M NaOH and extracted twice with 500 µL tert-307 
butyl methyl ether. The organic fractions were combined and dried over anhydrous MgSO4 and analysed 308 
by HPLC or GC-FID on a chiral stationary phase. For further details see the Supplementary Information 309 
(Section 4 & 5).  310 
Preparative-scale reactions were run using 100 mM D-glucose, 0.5 mM NADP+, 0.3 mg mL-1 GDH, 50 mM 311 
or 10 mM ketone, 2, 5 or 20 equivalents of amine, 0.1 to 0.5 mg mL-1 purified wild-type AspRedAm or 1.0 312 
mg mL-1 AspRedAm Q240A variant in 100 mM pH 9.0 Tris buffer. Reactions were incubated at 20°C or 313 
30°C, 250 rpm for 24 h. The reaction was basified to pH 12 with 10 M NaOH solution and the product 314 
extracted into diethyl ether or dichloromethane with intermediate centrifugation (4°C, 2,831 rcf, 5 min) 315 
to improve the separation of phases. The organic layers were combined, dried over anhydrous MgSO4 316 
and the solvent carefully concentrated. The residue was dissolved in dry diethyl ether and acidified with 317 
a solution of 2 M HCl in diethyl ether or purified by column chromatography. Further details can be 318 
found in the Supplementary Information (Section 13). 319 
Kinetic Assays 320 
The reductive aminase activity was measured using a modified method to that previously reported.24,52 321 
For substrate specificity screening, a typical reaction mixture contained 15 mM carbonyl compound, 60 322 
mM amine nucleophile from buffer stock adjusted to pH 9.3, 0.3 mM NADPH, 1ര% (v/v) 323 
dimethylsulfoxide and 5-100 ʅg of purified AspRedAm in a total volume of 200 ʅL (100 mM sodium 324 
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tetraborate, pH 9).  Activity measurements were performed in triplicate at 340 nm (ɸ = 6.22 mMо1രcmо1) 325 
or 370 nm (ɸ = 2.216 mMо1രcmо1) using a Tecan infinite M200 microplate reader (Tecan Group, 326 
Switzerland).  327 
Steady state kinetic measurements were performed with various concentrations of one substrate at 328 
different fixed concentrations of the second substrate while the third substrate was held at a constant 329 
level. Double reciprocal plots were obtained and line patterns were examined against rate equations 330 
describing sequential mechanisms. Product inhibition studies for the reductive amination of 1 and g, and 331 
the deamination of 1g were performed with various concentrations of the one substrate and fixed 332 
saturating concentrations of the other substrates in the presence of the product (inhibitor). Double 333 
reciprocal plots obtained were examined and data were fitted into equation describing competitive, 334 
non-competitive and uncompetitive inhibition. The reaction was initiated by the addition of purified 335 
AspRedAm to the mixture. A unit of AspRedAm was equal to the amount of the pure enzyme required to 336 
consume 1 ʅmol NADPH/ NADP+ per min. Activity measurements were performed in triplicate and 337 
kinetic constants were determined through nonlinear regression based on MichaelisMenten kinetics 338 
(QtiPlot software). For further details see Supplementary Information (Section 6). 339 
Protein Crystallization 340 
Purified AspRedAm was subjected to crystallisation trials using a range of commercially-available screens 341 
in 96-well sitting-drop format in which each drop consisted of 150 nL protein and 150 nL of precipitant 342 
reservoir solution. Crystallization experiments gave two structures of AspRedAm: an NADP(H) complex 343 
and also a ternary complex with NADP(H) and (R)-29a. For further details see Supplementary 344 
Information (Section 10). Crystals that diffracted to a resolution of equal to, or better than, 3 Å 345 
resolution were retained for dataset collection at the Diamond Light Source synchrotron. The coordinate 346 
files and structure factors have been deposited in the Protein DataBank (PDB) with coordinate accession 347 
numbers 5g6r [AspRedAm-NADP(H)] and 5g6s [AspRedAm-NADP(H)-(R)-rasagiline complex]. 348 
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Figure Captions: 498 
 499 
Figure 1. Examples of biocatalytic routes to chiral amines via monoamine oxidase catalysed resolution, or 500 
asymmetric synthesis catalysed by ammonia lyases, transaminases, amine dehydrogenases and imine 501 
reductases (IREDs). This work describes the reductive aminase from Aspergillus oryzae (AspRedAm) that is 502 
capable of performing imine formation as well as reduction to afford a wide variety of chiral amines.  503 
Figure 2. Reactivity chart for AspRedAm-catalysed reactions based on specific activities of a panel of carbonyl 504 
compounds and amine reacting partners. a) Chart displaying relative activity of amine/carbonyl pairs in 505 
reductive amination reactions. Compounds presented in the plot area are representative examples of products 506 
obtained in biotransformations. Conversions of >50% were achieved in all cases when the recommended 507 
amine:ketone ratios were used. Framed structures correspond to scaled-up biotransformations with isolated 508 
products. b) Carbonyl acceptors and amine nucleophiles arranged in Groups based on their average relative 509 
specific activity value. c) Legend for the reactivity chart with specific activity ranking and recommended ratio of 510 
amine to carbonyl compound for reductive amination. 511 
 512 
Figure 3. Reductive amination of 1 with g and kinetic model for AspRedAm showing sequential cofactor and 513 
substrate binding followed by product and cofactor release based on steady-state kinetic studies. Following 514 
binding of the nicotinamide cofactor (i), ketone is bound (ii), followed by the amine (iii), followed by enzyme-515 
catalysed imine formation and NADPH-mediated reduction. The amine product is then released (iv) prior to 516 
NADP+ (v). 517 
 518 
Figure 4. Structural and mutagenesis data of AspRedAm highlighting essential catalytic residues. a)  Dimeric 519 
structure of AspRedAm in complex with NADP(H) and (R)-29a dimer in which the active site is at the interface 520 
between the Rossman fold of one monomer and the C-terminal bundle of its neighbour; b) Active site of 521 
AspRedAm at dimer interface.  Electron density represents the 2Fo-Fc (blue) and Fo-Fc (omit, green) maps, the 522 
latter obtained prior to refinement of the ligand, and contoured at levels of 1.0 and 2.5 respectively. Distances 523 
25 
 
are shown in Ångstroms. c) Kinetic data of AspRedAm wild-type and mutants D169A, D169N and Y177A. 524 
Mutation at D169 and Y177 resulted in a marked decrease in activity suggesting essential roles for these 525 
residues in catalysis. 526 
527 
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Table 1. AspRedAm-catalysed reductive amination of carbonyl compounds. 528 
AspRedAm
NADPH NADP+
GlucoseGluconolactone
R1 R2
O
R1 R2
HN
R3
+ R3NH2
GDH
NHNHBu NHMe
NH
NH
NHMe NH2
N
NH
N
O
N
O
NHMeNHBu
NHNH
NHEt
NHBn
N
H
NH2NHMeNH NHNH NHBn
N
HN NHMe
N
Boc
NHMe
N
Cbz
NHMe
HN
NHMe
F
N
H
HN
HN
N
H
N
H
F
1a, (1 eq.), 94% conv. 1b, (1 eq.), 90% conv. 1c, (1 eq.), 73% conv. 1m, (1 eq.), 84% conv.1g, (2 eq.), 95% conv. 1k, (4 eq.), 47% conv.
1n, (20 eq.), 94% conv. (R)-1t, (20 eq.), 10% conv.
NH
(S)-1t, (20 eq.), 81% conv. 2a, (4 eq.), 97% conv. 2b, (4 eq.), >97% conv.
2c, (4 eq.), >97% conv. 5g, (4 eq.), 81% conv.5d, (20 eq.), 93% conv. 6g, (2 eq.), 72% conv.
>98% e.e. (R) 9a, (5 eq.), 45% conv.
97% e.e. (R)
9g, (5 eq.), 39% conv.
88% e.e. (R)
9k, (20 eq.), 37% conv.
97% e.e. (R)
10a, (20 eq.), >97% conv.
97% e.e. (R)
10b, (20 eq.), >97% conv.
82% e.e.
17c, (50 eq.), >97% conv.
30% e.e. (R)
17d, (50 eq.), >97% conv.
96% e.e. (R)
17g, (50 eq.), >97% conv.
85% e.e. (R)
17a, (20 eq.), >97% conv.
NHBn
19a, (4 eq.), 92% conv. 19f, (4 eq.), >97% conv.
19m, (4 eq.), >97% conv. 19m, (4 eq.), 50% conv.[a]19l, (2 eq.), 58% conv. 19p, (20 eq.), 40% conv. 23a, (50 eq.), >97% conv.
>98% e.e. (R)
27a, (5 eq.), 49% conv.
97% e.e. (R)
27g, (20 eq.), 54% conv.
>98% e.e. (R)
29a, (50 eq.), 64% conv.
95% e.e. (R)
30a, (50 eq.), 15% conv.
>98% e.e. (S)
30g, (50 eq.), <5% conv.
35g, (10 eq.), 53% conv. 36g, (10 eq.), 64% conv.
1 - 36
a - p
1a - 36g
 529 
Conversions determined by HPLC or GC-FID analysis. Reaction conditions: ketone/aldehyde (5 mM), amine (1 to 50 530 
eq.), AspRedAm (1 mg mL-1), NADP+(1 mM), GDH (0.2 mg mL-1), D-glucose (30 mM), Tris buffer (100 mM, pH 9.0), 531 
25°C, 250 rpm, 24 h. [a] Only the product of double reductive amination was observed.  532 
 533 
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Table 2. Comparison of stereochemical outcomes from biotransformations catalysed by AspRedAm variants 534 
W210A and Q240A.  535 
 536 
Entry Ketone Amine Product 
AspRedAm WT 
AspRedAm 
Q240A 
AspRedAm 
W210A 
Conv. 
(%) 
e.e. (%)
(R or S) 
Conv. 
(%) 
e.e. (%) 
(R or S) 
Conv.
(%) 
e.e (%) 
(R or S) 
1 17 c 17c >97 30 (R) 90 90 (R) >97 94 (S) 
2 17 d 
*
NHBu
17d >97 96 (R) 97 >98 (R) >97 70 (S) 
3 17 g 17g 72 85 (R) >97 >97 (R) >97 90 (S) 
4 17 k 17k 0 n.a. 56 >98 (R) 0 n.a. 
5 29 a *
NH
29a 64 95(R) >97 >98 (R) 65 31 (S) 
6 9 a 9a >97 88 (R) >97 >97 (R) >97 80 (S) 
7 10 c 10c >97 59[a] >97 85[a] >97 49 [a][b] 
 [a] Absolute configuration not assigned [b] gives opposite enantiomer to the wild-type enzyme. n.a. not 537 
applicable. N.B. Reactions carried out with 20 amine eq except for entry 5 (50 eq.). AspRedAm variant Q240A 538 
displayed improved (R)-selectivity compared to the wild-type enzyme whereas W210A mutant was (S)-selective for 539 
investigated substrates.  540 
 541 
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dehydrogenase
R1 R2
O
R1 R2
NH2
*
+ NH3 NADH NAD+
R1 R2
O
H2N
R3
+
R1
∗
R2
HN
R3
R1 R2
N
R3
-H2O
NADPH NADP+
IRED
AspRedAm
R3 R4
NH2
R3 R4
O
(1 eq.) (1 eq.)
  
O
O
O
1
2
3
O
OEt
O
O
O
O
O
O
4 5
O
O
6 7 8
9 10 11
12
O O
OEt
13
O
O
O
O
OEt
OO
O
O
O
O
14 15
16 17
18 20
22
O
21
19
O O O
O
O
O
O
O
O
O
O
OO
23
25
24
28 29 30
31 32
Gr
o
u
p 
IV
G
ro
u
p 
III
Gr
o
u
p 
II
G
ro
u
p 
I
NH2
NH2
NH2
a
b
c
NH2 NH2
NH2
d e
f g
NH2
H2N NH2
NH2
N
H
NH3 NH
NH2
NH2
NH
HO
N
H N
H
NH2
h i j k l m
n o p q r s
Gr
o
u
p 
A
Gr
o
u
p 
B
Gr
o
u
p 
C
O
F
27
O
26
NH2
H2N
H2N
 
Reactivity Area Specific activity range (U/mg) 
Recommended ratio of amine in 
reductive amination 
 2-9 1-4
 1-2 4-10
 0.4-1 10-20
 0.1-0.4 20-50
 <0.1 amination unlikely
Figure 2. Reactivity chart for AspRedAm-catalysed reactions based on specific activities of a panel of 
carbonyl compounds and amine reacting partners. a) Chart displaying relative activity of amine/carbonyl 
pairs in reductive amination reactions. Compounds presented in the plot area are representative examples 
of products obtained in biotransformations. Conversions of >50% were achieved in all cases when the 
recommended amine:ketone ratios were used. Framed structures correspond to scaled-up 
biotransformations with isolated products. b) Carbonyl acceptors and amine nucleophiles arranged in 
Groups based on their average relative specific activity value. c) Legend for the reactivity chart with specific 
activity ranking and recommended ratio of amine to carbonyl compound for reductive amination. 
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AspRedAm
NADPH NADP++ MeNH2 + +
O NHMe
1
g
1g
MeNH2
NADPHNADP+
Enz
Enz: NADPH
Enz: NADPH/KetoneEnz: NADPH/Ketone/Amine
Enz: NADP+
AspRedAm
Catalytic
Cycle
ONHMe
i
ii
iii
iv
v
  
  
Enzyme variants Km (mM) kcat (s
-1) kcat/Km (s
-1 mM-1) Km (ketone) kcat (s
-1) kcat/Km (s
-1 mM-1)
wild-type 0.352 3.243 9.213 1.901 1.470 0.733
D169A 1.101 0.016 0.014 2.700 0.008 0.003
D169N 0.320 0.009 0.028 2.080 0.007 0.003
Y177A 0.689 0.063 0.091 2.212 0.050 0.023
Figure 4. Structural and mutagenesis data of AspRedAm highlighting essential catalytic residues. a)  Dimeric 
structure of AspRedAm in complex with NADP(H) and (R)-29a dimer in which the active site is at the 
interface between the Rossman fold of one monomer and the C-terminal bundle of its neighbour; b) Active 
site of AspRedAm at dimer interface.  Electron density represents the 2Fo-Fc (blue) and Fo-Fc (omit, green) 
maps, the latter obtained prior to refinement of the ligand, and contoured at levels of 1.0 and 
2.5 respectively. Distances are shown in Ångstroms. c) Kinetic data of AspRedAm wild-type and mutants 
D169A, D169N and Y177A. Mutation at D169 and Y177 resulted in a marked decrease in activity suggesting 
essential roles for these residues in catalysis. 
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NH
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17d, (50 eq.), >97% conv.
96% e.e. (R)
17g, (50 eq.), >97% conv.
85% e.e. (R)
17a, (20 eq.), >97% conv.
NHBn
19a, (4 eq.), 92% conv. 19f, (4 eq.), >97% conv.
19m, (4 eq.), >97% conv. 19m, (4 eq.), 50% conv.[a]19l, (2 eq.), 58% conv. 19p, (20 eq.), 40% conv. 23a, (50 eq.), >97% conv.
>98% e.e. (R)
27a, (5 eq.), 49% conv.
97% e.e. (R)
27g, (20 eq.), 54% conv.
>98% e.e. (R)
29a, (50 eq.), 64% conv.
95% e.e. (R)
30a, (50 eq.), 15% conv.
>98% e.e. (S)
30g, (50 eq.), <5% conv.
35g, (10 eq.), 53% conv. 36g, (10 eq.), 64% conv.
1 - 36
a - p
1a - 36g
AspRedAm 
(wild-type or variant)
NADPH NADP+
GlucoseGluconolactone
R1 R2
O
R1
∗
R2
HN
R3
+ R3NH2
GDH
∗
NH
∗
NHBu
∗
NHMe
∗
NH2
∗
NH
∗ NH
N
∗
O
